SEC Form SC 13G/A filed

$SSKN
Medical/Dental Instruments
Health Care
Get the next $SSKN alert in real time by email
SC 13G/A 1 tm216457-19_sc13ga.htm SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

 

STRATA SKIN SCIENCES, INC.

(Name of Issuer)

 

Common Stock, $0.001 par value

(Title of Class of Securities)

 

86272A206

(CUSIP Number)

 

December 31, 2020

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x  Rule 13d-1(b)
¨  Rule 13d-1(c)
¨  Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Continued on following pages

Page 1 of 7 Pages

 

 

 

 

 

CUSIP NO.  86272A206 Page 2 of 7 Pages

 

CUSIP No.  86272A206
(1) Names of reporting persons Nantahala Capital Management, LLC
(2) Check the appropriate box if a member of a group (a)
(see instructions) (b)
(3) SEC use only  
(4) Citizenship or place of organization MA
Number of shares beneficially owned by each reporting person with:  
(5) Sole voting power 0
(6) Shared voting power 4,683,908
(7) Sole dispositive power 0
(8) Shared dispositive power 4,683,908
(9) Aggregate amount beneficially owned by each reporting person 4,683,908
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
(11) Percent of class represented by amount in Row (9) 13.9%
(12) Type of reporting person (see instructions) IA

 

 

 

 

CUSIP NO.  86272A206 Page 3 of 7 Pages

 

CUSIP No.  86272A206
(1) Names of reporting persons Wilmot B. Harkey
(2) Check the appropriate box if a member of a group (a)
(see instructions) (b)
(3) SEC use only  
(4) Citizenship or place of organization USA
Number of shares beneficially owned by each reporting person with:  
(5) Sole voting power 0
(6) Shared voting power 4,683,908
(7) Sole dispositive power 0
(8) Shared dispositive power 4,683,908
(9) Aggregate amount beneficially owned by each reporting person 4,683,908
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
(11) Percent of class represented by amount in Row (9) 13.9%
(12) Type of reporting person (see instructions) HC

 

 

 

 

CUSIP NO.  86272A206 Page 4 of 7 Pages

 

CUSIP No.  86272A206
(1) Names of reporting persons Daniel Mack
(2) Check the appropriate box if a member of a group (a)
(see instructions) (b)
(3) SEC use only  
(4) Citizenship or place of organization USA
Number of shares beneficially owned by each reporting person with:  
(5) Sole voting power 0
(6) Shared voting power 4,683,908
(7) Sole dispositive power 0
(8) Shared dispositive power 4,683,908
(9) Aggregate amount beneficially owned by each reporting person 4,683,908
(10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
(11) Percent of class represented by amount in Row (9) 13.9%
(12) Type of reporting person (see instructions) HC

 

Item 1(a). Name of Issuer:
   
 

STRATA SKIN SCIENCES, INC. (the “Issuer”).

   
Item 1(b). Address of the Issuer's Principal Executive Offices:
   
  5 Walnut Grove Drive, Suite 140, Horsham, Pennsylvania 19044
   
Item 2(a). Name of Person Filing
   
 

Nantahala Capital Management, LLC (“Nantahala”)

Wilmot B. Harkey

Daniel Mack (together the “Reporting Persons”)

   
Item 2(b). Address of Principal Business Office or, if None, Residence:
   
 

130 Main St. 2nd Floor

New Canaan, CT 06840

 

Item 2(c). Citizenship:
   
 

Nantahala is a Massachusetts limited liability company.

Each of Messrs. Harkey and Mack is a citizen of the United States of America.

   
Item 2(d).

Title of Class of Securities:

 

 

Common Stock, $0.001 par value (the “Shares”).

 

 

 

 

CUSIP NO.  86272A206 Page 5 of 7 Pages

 

Item 2(e). CUSIP Number:
 

 

86272A206

 

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

 

 

(a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

 

(e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

 

(f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

 

(g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

 

(h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

(i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

(j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

 

Item 4.

 

Ownership:

   
Item 4(a).

Amount Beneficially Owned:

 

As of December 31, 2020, Nantahala may be deemed to be the beneficial owner of 4,683,908 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

   
Item 4(b).

Percent of Class:

 

As of December 31, 2020, each of the Reporting Persons may be deemed to be the beneficial owner of 13.9% of the total number of Shares outstanding (based upon information provided by the Issuer on a 10-Q filed November 10, 2020, there were 33,769,909 Shares outstanding as of November 6, 2020).

 

 

 

 

CUSIP NO.  86272A206 Page 6 of 7 Pages

 

Item 4(c). Number of shares as to which such person has:

 

 

Nantahala Capital Management, LLC

 

  (i) Sole power to vote or direct the vote 0
  (ii) Shared power to vote or to direct the vote 4,683,908
  (iii) Sole power to dispose or to direct the disposition of 0

(iv) Shared power to dispose or to direct the disposition of 4,683,908

 

 

Each of Messrs. Harkey and Mack:

 

  (i) Sole power to vote or direct the vote 0
  (ii) Shared power to vote or to direct the vote 4,683,908
  (iii) Sole power to dispose or to direct the disposition of 0
  (iv) Shared power to dispose or to direct the disposition of 4,683,908

 

Item 5. Ownership of Five Percent or Less of a Class:
   
 

This Item 5 is not applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person:
   
 

Nantahala Capital Partners SI, LP, a fund advised by Nantahala, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, approximately 6.9% of the outstanding shares of common stock beneficially owned by Nantahala reported herein.

   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
   
 

Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E). See Item 4(a).

   
Item 8. Identification and Classification of Members of the Group:
   
  This Item 8 is not applicable.
   
Item 9. Notice of Dissolution of Group:
   
  This Item 9 is not applicable.
   
Item 10. Certification:
   
 

By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

 

 

 

 

CUSIP NO.  86272A206 Page 7 of 7 Pages

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

 

Date:  February 12, 2021 NANTAHALA CAPITAL MANAGEMENT, LLC
     
  By: /s/ Paul E. Rehm
    Paul E. Rehm
    Chief Compliance Officer
     
  /s/ Wilmot B. Harkey
  Wilmot B. Harkey
     
  /s/ Daniel Mack
  Daniel Mack

 

 

Get the next $SSKN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SSKN

DatePrice TargetRatingAnalyst
More analyst ratings

$SSKN
Press Releases

Fastest customizable press release news feed in the world

See more
  • STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update

    HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter and year ended December 31, 2024, and provides a corporate update. Fourth Quarter and Full-Year 2024 Financial Highlights Revenue in the fourth quarter of 2024 was $9.6 million, up 10% from $8.7 million in the year-ago quarter Global net recurring XTRAC® revenue in the fourth quarter was $5.5 million vs. $5.4 million in the prior year period, with international growth of 13%

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

    HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light

    HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the results of a newly published study in Japan that further validates the technological advantages of high repetition rate, high dose, coherent collimated narrow band Excimer Laser technology over other sources of UVB light that are less accurate, lack the repetition rate and/or fluence capabilities of an Excimer Light for treating Vitiligo, Psoriasis, Alopecia Areata and Atopic Dermatitis. The study, titled "Exci

    $SSKN
    Medical/Dental Instruments
    Health Care

$SSKN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$SSKN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SSKN
SEC Filings

See more

$SSKN
Leadership Updates

Live Leadership Updates

See more
  • Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

    HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

    HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

    $SSKN
    Medical/Dental Instruments
    Health Care

$SSKN
Financials

Live finance-specific insights

See more
  • STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update

    HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report fourth quarter and year end 2024 financial results on Thursday, March 27, 2025 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Thursday, March 27, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interest

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences to Report Third Quarter 2024 Financial Results on November 13, 2024 and Provide Corporate Update

    HORSHAM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report third quarter 2024 financial results on Wednesday, November 13, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, November 13, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested part

    $SSKN
    Medical/Dental Instruments
    Health Care
  • STRATA Skin Sciences to Report Second Quarter 2024 Financial Results on August 14, 2024 and Provide Corporate Update

    HORSHAM, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2024 financial results on Wednesday, August 14, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, August 14, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested parties

    $SSKN
    Medical/Dental Instruments
    Health Care

$SSKN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more